Good day readers! Welcome to our latest GPCR updates.
This week's highlights:
Dr. Yamina Berchiche, Founder and Director of Dr. GPCR, was featured as Superluminal Medicines Launches to Drug Protein Conformations in a Flash.
Our partner, Domain Therapeutics, will attend the SACHS 23rd annual biotech event in Europe.
Dr. Gregory Tall and team's study on GPR114/ADGRG5, activated by tethered-peptide-agonist, a cleaved adhesion GPCR.
Dr. Christopher Langmead and colleagues' work on the 5-HT2C receptor as a therapeutic target for substance use disorders.
Save these dates:
November 2 - 4: The GPCR Retreat is approaching and we are thrilled to be sponsors! Submit poster abstracts here; short talks will be selected from Abstracts. Abstract submissions close on October 2, and final registration ends on September 21.
Subscribe to the Dr. GPCR Newsletter for more insights!
Now, explore the Classified GPCR News from September 4th to 10th, 2023.